Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor. GB affects 3.2 in 100,000 people who have an average survival time of around 14 m...

Full description

Bibliographic Details
Main Authors: Hannah Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D. Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Biomedicines
Subjects:
temozolomide (TMZ), triazene compounds
alkylating agents
brain tumor
glioblastoma
Online Access:https://www.mdpi.com/2227-9059/7/3/69

Internet

https://www.mdpi.com/2227-9059/7/3/69

Similar Items